Načítá se...
Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains
The characterization of kinases as oncogenic drivers has led to more than 30 FDA-approved targeted kinase inhibitors for cancer treatment. Unfortunately, these therapeutics fail to have clinical durability because of adaptive responses from the kinome and transcriptome that bypass inhibition of the...
Uloženo v:
| Vydáno v: | Mol Cell Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4845204/ https://ncbi.nlm.nih.gov/pubmed/27308566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1052182 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|